Neurovalens wins FDA nod for weight management neurostim device
December 11, 2025
Neurovalens announced that it received FDA de novo approval for Modius Lean, its non-invasive neurotechnology for weight management.
Neurovalens announced that it received FDA de novo approval for Modius Lean, its non-invasive neurotechnology for weight management.
Flow Neuroscience’s at-home depression treatment device has become the first of its kind to be approved by the FDA.
Lumos Labs’ LumosityRx is positioned for use alongside other ADHD treatment modalities such as medication and therapy.
GRAND BLANC, Mich., Dec. 10, 2025 /PRNewswire/ — ModuleMD, ranked as one of America’s fastest-growing companies on the Inc. 5000 and top-rated EHR vendor on G2, announces SkinSight™ AI, a solution that brings automation, accuracy, and consistency to one of the most manual and variable workflows in allergy care: skin test measurement and documentation.
A new, soft, all-in-one, wearable system has been designed for continuous wireless monitoring of neonatal health in low-resource settings.
Synaptic plasticity—the brain’s ability to modify the connections between neurons to support learning—is one of the neural functions profoundly altered in Huntington’s disease, with a direct impact on brain function.
In Brazil, researchers from the Federal University of Grande Dourados (UFGD), the State University of Campinas (UNICAMP), and São Paulo State University (UNESP) have conducted a study that confirmed the safety and anti-inflammatory, analgesic, and anti-arthritic properties of the Joseph’s Coat plant (Alternanthera littoralis).
Ceribell (Nasdaq:CBLL) announced that it received FDA 510(k) clearance for its proprietary delirium monitoring solution.
HeartBeam (Nasdaq:BEAT) announced today that it received FDA 510(k) clearance for its 12-lead electrocardiogram (ECG) synthesis software.
Intuitive (NASDAQ: ISRG)+
announced today that the FDA cleared its da Vinci single port (SP) surgical robot for use in new types of procedures.